Episode 63
We look at Vosoritide, a promising, potential treatment for children with genetic short stature who do not have chondrodysplasia. Host Aaron Lohr talks with Andrew Dauber, MD, division chief of endocrinology at Children’s National Hospital. Dr. Dauber and colleagues presented about Vosoritide at ENDO 2022. Their abstract is titled, “A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature.”
Join our endocrine community and become a member! Only members receive access to a variety of member benefits that will enhance your career. If your membership has lapsed, rejoin today so that you can continue to receive your membership benefits.
Our top-ranked peer-reviewed journals are among the first to publish major developments and discovery milestones.
We empower high-quality, equitable healthcare for people with hormone health conditions, including diabetes and obesity, infertility, thyroid conditions, osteoporosis, and hormone-related cancers. Together, we promote an environment that helps people of all backgrounds and ethnicities access the medical care they need.
